Acute myeloid leukemia with multilineage dysplasia
MONDO:0019456An acute myeloid leukemia arising de novo and not as a result of treatment. It is characterized by the presence of myelodysplastic features in at least 50% of the cells of at least two hematopoietic cell lines. Patients often present with severe cytopenia.
Also known as: AML with multilineage dysplasia, AML with myelodysplasia-related features, De novo acute myeloid leukaemia with multilineage dysplasia, De novo acute myeloid leukemia with multilineage dysplasia, acute myeloid leukaemia with myelodysplasia-related features, acute myeloid leukemia with myelodysplasia-related features
3112 clinical trials for this condition and its sub-types, 34 tagged with Acute myeloid leukemia with multilineage dysplasia itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
-
Could detoxing metals boost chemo for leukemia?
Disease control Recruiting nowThis early-stage trial is testing whether two drugs that lower metal levels in the body can help people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) respond better to chemotherapy. The study will enroll 58 adults and aims to find the safest dose and check f…
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New hope for Tough-to-Treat leukemia: multiple drug cocktails tested
Disease control Recruiting nowThis phase II trial tests several experimental drug combinations against the standard treatment for high-risk acute myeloid leukemia (AML) in patients aged 59 or younger. The goal is to see if newer regimens, including venetoclax and liposome formulations, can better shrink cance…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Immune booster: personalized NK cells aim to wipe out blood cancer after transplant
Disease control Recruiting nowThis phase 2 trial tests whether giving patients their own personalized natural killer (NK) cells after chemotherapy and a cord blood transplant can help kill any remaining cancer cells. The study includes 100 people with various blood cancers like leukemia, lymphoma, and multipl…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
New drug cocktail aims to outsmart relapsed leukemia
Disease control Recruiting nowThis early-phase trial is testing whether adding ruxolitinib to the standard drugs azacitidine and venetoclax is safe for people with acute myeloid leukemia (AML) that has come back or not responded to treatment. About 51 adults will receive the three-drug combination to find the…
Phase 1 • Sponsor: Jennifer Saultz • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Radioactive antibody targets cancer before stem cell transplant in High-Risk leukemia trial
Disease control Recruiting nowThis study tests a radioactive antibody (211At-BC8-B10) that seeks out and attacks cancer cells, followed by a donor stem cell transplant for people with high-risk leukemia or myelodysplastic syndrome (MDS) that has returned or not responded to treatment. The goal is to find the …
Phase 1/2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Radioactive antibody could boost stem cell transplant success in tough leukemias
Disease control Recruiting nowThis study is testing a new approach for people with high-risk acute leukemias or myelodysplastic syndrome. Before a donor stem cell transplant, patients receive a radioactive antibody (211At-BC8-B10) designed to target and kill cancer cells while sparing healthy tissue. The goal…
Phase 1/2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New screening trial aims to speed up matching of cancer patients to the right treatments
Knowledge-focused Recruiting nowThis study tests a new way to screen patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) by analyzing their bone marrow and blood for specific biomarkers. The goal is to quickly match patients with a treatment trial that targets their cancer's unique mark…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Blood bank aims to predict leukemia risk in MDS patients
Knowledge-focused Recruiting nowThis study gathers blood and bone marrow samples from 150 adults with myelodysplastic syndrome (MDS), a blood disorder that can turn into acute leukemia. Researchers want to find biological markers that help predict which patients are likely to progress to leukemia. The goal is t…
Sponsor: University Hospital, Brest • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
Massive new study aims to unlock secrets of rare blood cancers
Knowledge-focused Recruiting nowThis long-term observational study is enrolling 5,000 adults with myeloproliferative neoplasms (MPNs)—rare blood cancers like polycythemia vera and myelofibrosis. Researchers will collect health records, patient surveys, and insurance data over at least five years to track sympto…
Sponsor: MPN Research Foundation • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC